Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

800 patients with rare gene mutation tracked for pancreatic cancer risk

NCT ID NCT07413029

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 800 people who carry a mutation in the PRSS1 gene, which causes hereditary pancreatitis. Researchers will collect health data and questionnaires to track how often pancreatic cancer develops and how the disease progresses over time. The goal is to better understand the natural history of this rare condition and improve future care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better predict pancreatic cancer risk in people with hereditary pancreatitis and improve monitoring guidelines.
What could go wrong
This is an observational study, not a treatment trial. It will not test any new drug or therapy, and results may take years to produce actionable insights.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 800 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Dec 2044

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Any patient, symptomatic or not, carrying a PRSS1 mutation detected in one of the 3 genetic laboratories carrying out this targeted genetic analysis in France. Children may be included in this study with the consent of their parents. People under guardianship or curatorship may also be included with the agreement of their guardian or curator.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Being a carrier of a known genetic mutation in the PRSS1 gene coding for cationic trypsinogen * Be followed in one of the participating centers Exclusion Criteria: * Opposition to data collection, expressed by the patient or one of their legal representatives

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hereditary pancreatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hereditary chronic pancreatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hereditary pancreatitis PRSS1 gene mutation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • REBOURS

    RECRUITING

    Clichy-sous-Bois, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.